“With exclusive global licensing rights to AXIM’s Eye Diagnostics portfolio, Verséa will be introducing a new innovative, rapid, tear-based, POC lab-testing platform designed specifically to assist eye-care clinicians in detecting and quantifying a variety of biomarkers associated with external ocular disorders.”   Verséa Ophthalmics, LLC, a business division of Verséa Holdings, Inc. (“Verséa”), signed exclusive...

Verséa Holdings, Inc. (“Verséa”) welcomes Rob Sambursky, MD, who joined the company as the President, effective as of August 5, 2022. Dr. Sambursky will support corporate strategy and operations as well as lead the company’s expansion into the ophthalmic market. Verséa recently launched a new business division, Verséa Ophthalmics, with a goal of providing innovative...